Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Main trialPhase 1
- “This is a first-in-human, multi-part clinical study designed to evaluate the safety, tolerability, pharmacokinetics (PK), food effect, and drug-drug interaction (DDI) potential of GV-100 following oral administration in healthy participants. The study is divided into four parts: Single Ascending Dose (SAD), Multiple Ascending Dose (MAD), Food Effect (FE), and Drug-Drug Interaction (DDI).”In the company’s words, NCT07788014 on ClinicalTrials.gov
Other drugs for ADPKD (Autosomal Dominant Polycystic Kidney Disease)
- DonidalorsenIonis Pharmaceuticals, Inc. · Phase 3
- NavenibartAstria Therapeutics, Inc. · Phase 3
- DeucrictibantPharvaris Netherlands B.V. · Phase 3
- ADX-324ADARx Pharmaceuticals, Inc. · Phase 3
- BerotralstatBioCryst Pharmaceuticals · Phase 3
- CAM2029Camurus AB · Phase 2/3
Coming up1
- 31 Mar 2027Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | 31 Mar 2027 | A Phase 1 Study of Single and Multiple Ascending Doses of GV-100 |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026